|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Colon cancer-associated B2 Escherichia coli colonize gut mucosa and promote cell proliferation显示文摘AIM:To provide further insight into the characterization of mucosa-associated Escherichia coli(E.coli)isolated from the colonic mucosa of cancer patients.METHODS:Phylogroups and the presence of cyclomodulin-encoding genes of mucosa-associated E.coli from colon cancer and diverticulosis specimens weredetermined by PCR.Adhesion and invasion experiments were performed with I-407 intestinal epithelial cells using gentamicin protection assay.Carcinoembryonic antigen-related cell adhesion molecule 6(CEACAM6)expression in T84 intestinal epithelial cells was measured by enzyme-linked immunosorbent assay and by Western Blot.Gut colonization,inflammation and procarcinogenic potential were assessed in a chronic infection model using CEABAC10 transgenic mice.Cell proliferation was analyzed by real-time mRNA quantification of PCNA and immunohistochemistry staining of Ki67.RESULTS:Analysis of mucosa-associated E.coli from colon cancer and diverticulosis specimens showed that whatever the origin of the E.coli strains,86%of cyclomodulin-positive E.coli belonged to B2 phylogroup and most harbored polyketide synthase(pks)island,which encodes colibactin,and/or cytotoxic necrotizing factor(cnf)genes.In vitro assays using I-407 intestinal epithelial cells revealed that mucosa-associated B2 E.coli strains were poorly adherent and invasive.However,mucosa-associated B2 E.coli similarly to Crohn’s disease-associated E.coli are able to induce CEACAM6expression in T84 intestinal epithelial cells.In addition,in vivo experiments using a chronic infection model of CEACAM6 expressing mice showed that B2 E.coli strain11G5 isolated from colon cancer is able to highly persist in the gut,and to induce colon inflammation,epithelial damages and cell proliferation.CONCLUSION:In conclusion,these data bring new insights into the ability of E.coli isolated from patients with colon cancer to establish persistent colonization,exacerbate inflammation and trigger carcinogenesis. | Jennifer Raisch Emmanuel Buc Mathilde Bonnet Pierre Sauvanet Emilie Vazeille Amélie de Vallée Pierre Déchelotte Claude Darcha Denis Pezet Richard Bonnet Marie-Agnès Bringer Arlette Darfeuille-Michaud | 2014 | World Journal of Gastroenterology2014，20，21： | 12 |
| 2 | Microbial markers in colorectal cancer detection and/or prognosis显示文摘Colorectal cancer(CRC) is the second leading cause of cancer worldwide. CRC is still associated with a poor prognosis among patients with advanced disease. On the contrary, due to its slow progression from detectable precancerous lesions, the prognosis for patients with early stages of CRC is encouraging. While most robust methods are invasive and costly, actual patient-friendly screening methods for CRC suffer of lack of sensitivity and specificity. Therefore, the development of sensitive, non-invasive and cost-effective methods for CRC detection and prognosis are necessary for increasing the chances of a cure. Beyond its beneficial functions for the host, increasing evidence suggests that the intestinal microbiota is a key factor associated with carcinogenesis. Many clinical studies have reported a disruption in the gut microbiota balance and an alteration in the faecal metabolome of CRC patients, suggesting the potential use of a microbialbased test as a non-invasive diagnostic and/or prognostic tool for CRC screening. This review aims to discuss the microbial signatures associated with CRC known to date, including dysbiosis and faecal metabolome alterations, andthe potential use of microbial variation markers for noninvasive early diagnosis and/or prognostic assessment of CRC and advanced adenomas. We will finally discuss the possible use of these markers as predicators for treatment response and their limitations. | Romain Villéger Amélie Lopès Julie Veziant Johan Gagnière Nicolas Barnich Elisabeth Billard Delphine Boucher Mathilde Bonnet | 2018 | World Journal of Gastroenterology2018，24，22： | 10 |
| 3 | A 'combined' levodopa test as a usefulmethod for evaluating the efficacy of dopamine agonists: application to pergolideand bromocriptine显示文摘 | Serre I Marconi R | 1995 | Mov Disord1995，10，5： | 1 |
| 4 | The L-dopa test in Par kinson's disease显示文摘 | Esteguy M Bonnet AM Kefalos J | 1985 | Rev Neurol (Paris)1985，141，： | 1 |
| 5 | Motor score of the unified Parkinson disease rating scale as a good predictor of Lewy body-asso- ciated neuronal loss in the substantia nigra显示文摘 | Greffard S Vemy M Bonnet AM | 2006 | Arch Neurol2006，63，： | 1 |
| 6 | Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease显示文摘 | Ibanez P Bonnet AM Debarges B | 2004 | Lancet2004，364，9440： | 1 |
| 7 | Developmental toxicities of methacrylic acid,ethyl methacrylate,n-butyl methacrylate,and allyl methacrylate in rats following inhalation exposure显示文摘 | Saillenfait AM Bonnet P Gallissot F | | 0，，01： | 1 |
| 8 | Involvement of Non-Dopaminergic Pathways in Park- inson's disease显示文摘 | Bonnet AM | 2000 | CNS Drugs2000，13，： | 1 |
| 9 | Nonmotor symptoms in Parkinson’s disease in 2012:relevant clinical aspects显示文摘 | Bonnet AM Jutras MF Czernecki V | 2012 | Parkinsons Dis2012，2012，19： | 1 |
| 10 | Urodynamic analysis in multiple system atrophy:characterisation of detrusor-sphincter dyssynergia显示文摘 | Bloch F Pichon B Bonnet AM | | 0，，12： | 1 |
| 11 | Hallucinations,REM sleep,and Parkinson's disease:a medical hypothesis显示文摘 | Arnulf I Bonnet AM Damier P | 2000 | Neurology2000，55，： | 1 |
| 12 | Eaely loss of mammalian target of rapamycin complex 1 ( mTORCI ) signaling and reducting in cell siza during dominant-negative suppression of hepatic nuclear factor 1-alpha (HNF1A) fanction in INS-1 insulinoma cells 显示文摘 | Farrelly AM Wobser H Bonnet C | 2009 | Diabetologia2009，52，1： | 1 |
| 13 | Does long-term aggra- vation of Parkinson's disease result from nondopaminergic lesions? 显示文摘 | Bonnet AM Loria Y Saint-Hilaire MH | 1987 | Neurology1987，37，9： | 1 |
| 14 | Effects of high-frequency stimulation on subthalamic neuronal activity in parkinsonian patients 显示文摘 | Welter ML Houeto JL Bonnet AM | 2004 | Arch Neurol2004，61，1： | 1 |
| 15 | Do parkinsonian symp- toms and levodopa-induced dyskinesias start in the foot? 显示文摘 | Vidai|het M Bonnet AM Marconi R | 1994 | Neu- rology1994，44，： | 1 |
| 16 | The Effects of Maternally Inhaled Formaldehyde on Embryonal and Foetal Development in Rats显示文摘 | Saillenfait AM Bonnet P Ceaurriz J | 1989 | Food Chem Toxicol1989，27，8： | 1 |
| 17 | Blood vessels change in themesencephalon of patients with Parkinson's disease 显示文摘 | Faucheux BA Bonnet AM Agid Y | 1999 | Lancet1999，353，9157： | 1 |
| 18 | Levodopa-induced dyskinesias are improved by fluoxetine显示文摘 | Vidailhet M Bonnet AM | 1995 | Neurology1995，45，10： | 1 |
| 19 | Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy bodyassociated neuronal loss in the substantia nigra显示文摘 | Greffard S Verny M Bonnet AM | 2006 | Arch Neurol2006，63，： | 1 |
| 20 | Conitive slcwing in Parkinson's disease fails to respond to levodopa treatment:the 15-objects test显示文摘 | Dubois B Bonnet AM | 1989 | Ne- urology1989，39，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员